Celebrating 10 Years of Trusted News Discovery
One News Page
> >

Clinigen buys U.S. rights to Novartis' cancer drug Proleukin

Reuters Wednesday, 13 February 2019
British pharmaceutical firm Clinigen Group Plc said on Wednesday it acquired the U.S. rights to Swiss drugmaker Novartis AG's skin and lung cancer drug Proleukin for a total of $210 million, including some future payments.

You Might Like

Tweets about this

Other recent news in Health

San Francisco moves to ban e-cigarettes until HEALTH effects knownCANADA to create national drug agency to cut cost of medicines
'Substantial factor': US JURY RULES AGAINST BAYER in Roundup cancer caseWENDY WILLIAMS Reveals She's Been Living in a Sober House
Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2019 One News Page Ltd. All Rights Reserved.
About us  |  Contact us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  In the News  |  DMCA / Content Removal  |  Privacy & Data Protection Policy
How are we doing? FeedbackSend us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter  •  FOLLOW us on Pinterest
One News® is a registered trademark of One News Page Ltd.